Contego Medical, Inc.

Contego Medical, Inc. is focused on developing advanced medical devices that enhance patient outcomes during vascular interventions, providing innovative solutions for healthcare professionals. Contego Medical, Inc. specializes in advanced medical devices that improve patient outcomes in vascular interventions.

The company was founded in 2005 and is headquartered in Raleigh, US. Ravish Sachar serves as both the founder and CEO. Contego Medical has successfully raised USD 22. 34 mn through 4 funding deals, with the latest funding round occurring on January 13, 2025, from returning investor Medtronic.

Contego Medical specializes in advanced medical devices aimed at improving patient outcomes in vascular interventions. Their core offerings include the Neuroguard IEP® System, which integrates a carotid stent, dilation balloon, and embolic protection to reduce stroke risk during carotid artery stenting. Additionally, they provide Excipio® Thrombectomy Devices and the Vanguard IEP® Peripheral Balloon Angioplasty System, focusing on effective thrombus removal while minimizing blood loss. These products primarily serve healthcare professionals in the United States, particularly in hospitals and surgical centers involved in vascular surgery and interventional cardiology.

Contego Medical generates revenue through direct sales of its medical devices, operating primarily on a B2B model with hospitals and surgical centers that require cardiovascular intervention products. The company engages clients through purchase agreements for specific products like the Neuroguard IEP® System and Excipio® Thrombectomy Devices, utilized in high-risk vascular procedures. While pricing specifics are not disclosed, the revenue model supports structured product distribution and partnerships within the healthcare sector, bolstered by a strategic alliance with Medtronic as the sole distributor in the United States. In January 2025, Contego Medical raised USD 22.

34 mn in venture funding from returning investor Medtronic. The company plans to utilize this funding to strengthen its product portfolio and expand its presence in emerging medical technologies. This includes the development of new products and potential market expansion into additional geographic regions, though specific details on these new products and target markets have not been disclosed.